These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33567808)

  • 21. Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.
    Oren YS; Irony-Tur Sinai M; Golec A; Barchad-Avitzur O; Mutyam V; Li Y; Hong J; Ozeri-Galai E; Hatton A; Leibson C; Carmel L; Reiter J; Sorscher EJ; Wilton SD; Kerem E; Rowe SM; Sermet-Gaudelus I; Kerem B
    J Cyst Fibros; 2021 Sep; 20(5):865-875. PubMed ID: 34226157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response.
    Pollak AJ; Zhao L; Crooke ST
    Nucleic Acid Ther; 2023 Apr; 33(2):95-107. PubMed ID: 36749166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective.
    Liang XH; De Hoyos CL; Shen W; Zhang L; Fazio M; Crooke ST
    Nucleic Acid Ther; 2021 Apr; 31(2):126-144. PubMed ID: 33534636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CpG oligonucleotides induce acute murine thrombocytopenia dependent on toll-like receptor 9 and spleen tyrosine kinase pathways.
    Johansson K; Maouia A; Rebetz J; Marcoux G; Shannon O; Italiano JE; Narayanan P; Henry S; Shen L; Semple JW
    J Thromb Haemost; 2024 Aug; ():. PubMed ID: 39155024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlations between preclinical BJAB assay ranking of antisense drugs and clinical trial adverse events.
    Partridge W; Burel SA; Ferng A; Xia S; Kwoh TJ; Henry SP; Baker BF
    Clin Transl Sci; 2023 Apr; 16(4):575-580. PubMed ID: 36631935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
    Billioud G; Kruse RL; Carrillo M; Whitten-Bauer C; Gao D; Kim A; Chen L; McCaleb ML; Crosby JR; Hamatake R; Hong Z; Garaigorta U; Swayze E; Bissig KD; Wieland S
    J Hepatol; 2016 Apr; 64(4):781-9. PubMed ID: 26658683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational design of antisense oligonucleotides modulating the activity of TLR7/8 agonists.
    Alharbi AS; Garcin AJ; Lennox KA; Pradeloux S; Wong C; Straub S; Valentin R; Pépin G; Li HM; Nold MF; Nold-Petry CA; Behlke MA; Gantier MP
    Nucleic Acids Res; 2020 Jul; 48(13):7052-7065. PubMed ID: 32544249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.
    Geiger T; Hüsken D; Weiler J; Natt F; Woods-Cook KA; Hall J; Fabbro D
    Anticancer Drug Des; 2000 Dec; 15(6):423-30. PubMed ID: 11716435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.
    Iraqi M; Perdomo J; Yan F; Choi PY; Chong BH
    Haematologica; 2015 May; 100(5):623-32. PubMed ID: 25682608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.
    Narayanan P; Shen L; Curtis BR; Bourdon MA; Nolan JP; Gupta S; Hoffmaster C; Zhou F; Christian B; Schaubhut JL; Greenlee S; Burel SA; Witztum JL; Engelhardt JA; Henry SP
    Toxicol Sci; 2018 Aug; 164(2):613-626. PubMed ID: 29846725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
    Wang Y; Diep JK; Yu RZ; Hurh E; Karwatowska-Prokopczuk E; Schneider E; Henry S; Bhanot S; Geary RS
    J Clin Pharmacol; 2023 Jan; 63(1):21-28. PubMed ID: 35801818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen.
    Knight CG; Morton LF; Onley DJ; Peachey AR; Ichinohe T; Okuma M; Farndale RW; Barnes MJ
    Cardiovasc Res; 1999 Feb; 41(2):450-7. PubMed ID: 10341844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation.
    Ruef J; Kuehnl P; Meinertz T; Merten M
    Platelets; 2008 Aug; 19(5):359-64. PubMed ID: 18791942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
    Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
    J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.